1[1]Dominguez-Munoz JE.Targeting the abnormalities of gastroduodenal functions in functional dyspepsia[J].Dig Dis,2001,19(3)∶195-200.
2[2]Iwanaga Y,Miyashita N,Saito T,et al.Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs[J].Jpn J Pharmacol,1996,71(2)∶129-137.
3[3]Iwanaga Y,Kimura T,Miyashita N,et al.Characterization of acetylcholinesterase-inhibition by itopride[J].Jpn J Pharmacol,1994,66(3)∶317-322.
4[4]Harasawa S,Miwa T.Effect of itopride hydrochloride on gastric emptying in chronic gastritis patients[J].Jpn Pharmacol Ther,1993,11(21)∶4189-4195.
5[5]Nakajima M,Uematsu T,Nakajima S.Phase I study of HSR-803[J].Jpn Pharmacol Ther,1993,11(21)∶4157-4173.
6[6]Mushiroda T,Douya R,Takahara E,et al.The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride,a gastroprokinetic agent:comparison with cisapride and mosapride citrate[J].Drug Metab Dispos,2000,28(10)∶1231-1237.
7[7]Miyoshi A,Omata S,Miwa T,et al.Clinical effect of HSR-803 on digestive symptoms:early phase Ⅱ study[J].Jpn Pharmacol Ther,1993,11(21)∶4175-4187.
8[8]Miyoshi A,Masamune O,Sekiguchi T,et al.Clinical evaluation of itopride hydrochloride for gastrointestinal symptoms associated with chronic gastritis:multi-center double-blind clinical trial using cisapride as control drug[J].Jpn Pharmacol Ther,1994,12(4)∶261-279.
9[9]Miyoshi A,Masamune O,Sekiguchi T,et al.Dose finding study of a gastroprokinetic agent,HSR-803,on gastrointestinal complations: late phase II study[J].Jpn Pharmacol Ther,1993,11(3)∶2107-2128.
10[10]Hirakawa T,Yoshizawa M,Kagawa T,et al.Clinical effect of the peristalsis enhancer itopride hydrochloride on the digestive symptoms of chronic gastritis[J].Clinical Report,1993,15(27)∶5901-5906.
